VXA-G1.1-NN Oral Vaccine
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Norovirus Gastroenteritis
Conditions
Norovirus Gastroenteritis
Trial Timeline
Apr 7, 2017 → May 6, 2018
NCT ID
NCT03125473About VXA-G1.1-NN Oral Vaccine
VXA-G1.1-NN Oral Vaccine is a phase 1 stage product being developed by Vaxart for Norovirus Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03125473. Target conditions include Norovirus Gastroenteritis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03125473 | Phase 1 | Completed |
Competing Products
11 competing products in Norovirus Gastroenteritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine Tablet | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-T | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN | Vaxart | Phase 1/2 | 33 |
| VXA-G1.1-NN | Vaxart | Phase 1 | 25 |
| Norwalk GI.1 Virus | Vaxart | Phase 1 | 25 |
| VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum | Vaxart | Phase 1/2 | 33 |
| Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + Placebo | Vaxart | Phase 2 | 44 |
| VXA-G1.1-NN + VXA-G2.4-NS + Placebo Tablets | Vaxart | Phase 1 | 25 |
| VXA-GI.1.NN + Placebo Tablet | Vaxart | Phase 1 | 25 |
| CDI-988 + Placebo | Cocrystal Pharma | Phase 1/2 | 33 |